Actinic Keratoses
Conditions
Keywords
Actinic Keratoses, Photodynamic Therapy, PDT, Blue Light
Brief summary
A double-blind, placebo controlled study conducted at a single study site. Evaluating the role of systemic antihistamine therapy in the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.
Interventions
DRUGAntihistamine Cetirizine Hydrochloride
Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
OTHERPlacebo
Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
Sponsors
DUSA Pharmaceuticals, Inc.
Goldman, Butterwick, Fitzpatrick and Groff
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age \> 18 * Subjects with 5-20 actinic keratosis of the face * Patients undergoing photodynamic therapy (PDT) to the face for AK with 5-aminolevulinic acid (ALA) activated by blue light. * Must be willing to give and sign a HIPPA form, photo consent and informed consent form. * Must be willing to comply with study dosing and complete the entire course of the study. * Female patients will be either of non-childbearing potential defined as: 1. Having no uterus 2. No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as: 1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device 2. Intrauterine coil 3. Bilateral tubal ligation 4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom) 5. Abstinence (If practicing abstinence must agree to use barrier method described above (d) if becomes sexually active). 6. Vasectomized partner g. Negative urine pregnancy test results Baseline prior to study entry (if applicable)
Exclusion criteria
* Presence of incompletely healed wound in treatment area * Presence of known or suspected BCC or SCC in treatment area * Previous PDT or treatment of the face with any topical cytotoxic or immunomodulatory agent for AKs within the past 6 months * Co-existing potentially confounding skin condition within treatment area (e.g. eczema, psoriasis, XP, rosacea) at investigator's discretion * Presence of tattoo and/or scar in the treatment area that in the investigators opinion would interfere with study assessments * Subjects with known photosensitivity or taking photosensitizing medications listed below: 1. Oral diabetes medicines 2. Griseofulvin 3. Thiazide diuretics 4. Sulfonylureas 5. Phenothiazines 6. Tetracycline's 7. St. John's Wort * Use of oral/topical retinoids within 1 month of Baseline * Subjects with a history of sensitivity to porphyrins * Subjects with recently excessive exposure of the treatment area to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or expectations of tanning during the time of the study * Female subjects who are pregnant, nursing an infant or planning a pregnancy during the study \[throughout the course of the study * Presence or evidence of any conditions that in the opinion of the investigator might impede the subject's ability to give consent or comply with protocol requirements. * Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study * History of non-compliance with clinical research protocols * Ablative laser resurfacing to on their face within 12 months * Non-ablative laser or light procedures to their face within the past 3 months * Microdermabrasion (light or medium skin peel) treatment on their face within the past 30 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Localized Skin Response | Up to day 180 | Localized Skin Response consisting of erythema, edema, crusting, exudation, Vesiculation/Pustulation and erosion/ ulceration Investigator evaluated on a standardized scale |
Countries
United States
Outcome results
None listed